← boardnext 2027-09
XFOR
X4 Pharmaceuticalsdistress 6/10 · elevated risk$3.67-1%today-21% from 52w high
Lead: Neutropenia · target CXCR4
Revenue
pre-revenue
Liquidity
$217M
Runway
2.3 yrs
Shares 1y
+727%
Price & events
-2.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.7%
1D
-4.2%
1W
-8.2%
1M
-14.3%
3M
-0.8%
6M
+144.7%
1Y
-85.2%
2Y
-97.9%
5Y
-98.2%
All
Overview
- Market Cap
- $346.15M
- Enterprise Value
- $204.25M
- Volume
- 24.50K
- 52 Week Range
- $1.42 – $4.67
- Total Shares
- 94.32M
- Float Shares
- 57.53M
- Short %
- 5.85%
- % Held by Insiders
- 0.54%
- % Held by Institutions
- 99.77%
- RVOL
- 0.03x
- Beta
- 0.35
Pipeline stages · 1 programs
Mavorixafor
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-09 Estimated 50% readout ~2027-11-15 | Phase 3 | Mavorixafor | Neutropenia | — | recruiting |
| 2026-03 | Phase 1 | Mavorixafor | Hepatic Insufficiency | 48 | recruiting |
| 2025-12 | Phase 3 | Mavorixafor, Placebo | WHIM Syndrome | 31 | active not recruiting |
| 2025-05-19 | Phase 1 | Mavorixafor, Carbamazepine, Efavirenz | Healthy Participants | 38 | completed |
Catalyst news & presentations · 3
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025-08-13partnershipClosed $85M private placement of common stock and pre-funded warrantsSEC 8-K
- 2025-01-13partnershipmavorixafor · Exclusive license to Norgine for EEA, Switzerland, UK, Australia, NZSEC 8-K
Approved drugs (1)
- XOLREMDIMAVORIXAFOR2024 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $12 (+216% upside) · 5 analysts
- 2026-07-10Wells FargoOverweight
- 2026-06-02Leerink PartnersOutperform
- 2026-03-09GuggenheimBuy
- 2025-12-05StifelBuy
- 2025-11-10HC Wainwright & Co.Buy
- 2025-08-29StifelBuy
Competitors — CXCR4
- none identified
Recent news
- 2026-07-18X4 Pharmaceuticals Inc (XFOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
- 2026-07-14Wells Fargo Initiates X4 Pharmaceuticals(XFOR.US) With Buy Rating, Announces Target Price $11 - 富途牛牛
- 2026-07-13X4 Pharmaceuticals (XFOR) Proxy filing Summary - Quartr
- 2026-07-12X4 Pharmaceuticals (XFOR) Q1 2026 earnings summary - Quartr
- 2026-07-12X4 Pharmaceuticals (XFOR) Proxy filing Summary - Quartr
- 2026-07-12X4 Pharmaceuticals (XFOR) Q4 2025 earnings summary - Quartr
- 2026-07-12X4 Pharmaceuticals (XFOR) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary - Quartr
- 2026-07-12X4 Pharmaceuticals (XFOR) Corporate presentation Summary - Quartr
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.